Atlas Trials

Anlotinib Combined With Dose-dense Temozolomide for the First Recurrent or Progressive Glioblastoma After STUPP Regimen

Clinical trial NCT04547855 · UNKNOWN

Trial details

NCT number
NCT04547855
Sponsor
Yonggao Mou
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Glioblastoma
Start date
2020-09-11
Primary completion
2022-09-11
Enrollment
54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.